Terrance McGuire - Pulmatrix Insider

PULM -- USA Stock  

USD 0.42  0.0251  6.41%

  Director
Mr. Terrance G. McGuire is Independent Director of the Company. Mr. McGuire was previously a director of Pulmatrix Operating from May 2006 until the date of the Merger. Mr. McGuire cofounded Polaris Partners in 1996 and is currently one of their General Partners. Prior to starting Polaris Partners, Mr. McGuire spent seven years at Burr, Egan, Deleage Co., investing in early stage medical and information technology companies. He currently serves on the board of directors of two public companies Acceleron Pharma Inc. and Ironwood Pharmaceuticals Inc. Mr. McGuire also serves on the boards of several private companies, including Adimab, Alector, Quantum Designs, Inc., Arsenal Medical480 Biomedical, Iora Health and MicroCHIPS. Mr. McGuire has formerly served on the board of directors of Editas, Life Line Screening, NextCode, Trevena and Saga, among others. Mr. McGuire is the former chairman of the National VC Association, chairman of the board of the Thayer School of Engineering at Dartmouth College, and a member of the boards of The David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology and The Arthur Rock Center for Entrepreneurship at Harvard Business School
Age: 60  Director Since 2015  MBA    
781-357-2333  http://pulmatrix.com
McGuire earned a B.S. in physics and economics from Hobart College, an M.S. in engineering from The Thayer School at Dartmouth College, and an M.B.A. from Harvard Business School.

Terrance McGuire Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (56.63) % which means that it has lost $56.63 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (125.11) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Showing few of many executives

DIRECTOR Since

Michael BlaszykNantKwest
2015
James LoughlinEdge Therapeutics
2011
Fred MiddletonEndocyte
2001
Lesley RussellEndocyte
2017
Kurt ContiEdge Therapeutics
2010
Ken LuChina Cord Blood Corporation
2009
Ann HanhamEndocyte
2004
John BellDelMar Pharmaceuticals
2013
Cooper RussellEndocyte
2013
Colin GoddardEndocyte
2013
Marc KozinEndocyte
2012
Frederick DriscollNantKwest
2017
Richard KusserowNantKwest
2014
Patrick MachadoEndocyte
2018
Robert SpiegelEdge Therapeutics
2013
Erich MohrDelMar Pharmaceuticals
2017
Dennis BrownDelMar Pharmaceuticals
2013
Napoleone FerraraDelMar Pharmaceuticals
2018
James HealyEdge Therapeutics
2015
Saiid ZarrabianDelMar Pharmaceuticals
2018
John ThomasNantKwest
2014

Entity Summary

Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted technology. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts. Pulmatrix operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 24 people.Pulmatrix (PULM) is traded on BATS Exchange in USA. It is located in MASSACHUSETTS U.S.A and employs 24 people. Pulmatrix was previously known as PULMATRIX INC and was traded on BATS Exchange under the symbol RTGN. Pulmatrix is listed under Pharmaceutical Products category by Fama And French industry classification.

Pulmatrix Leadership Team

Terrance McGuire, Director
Matthew Sherman, Director
David Hava, Chief Scientific Officer
Akihisa Akao, Director
James Roach, Chief Medical Officer
Michael Higgins, Director
Steven Gillis, Director
Jean Sung, Vice President - Pharmaceutical Development
William Duke, CFO, Principal Financial Officer & Principal Accounting Officer
Robert Clarke, CEO and President and Director
Scott Rocklage, Director
Kurt Graves, Director
Richard Conley, Independent Director
Mark Iwicki, Chairman of the Board
Amit Munshi, Director
Gregory French, Independent Director
David JD, Advisor

Stock Performance Indicators

Did you try this?

Run Portfolio Center Now

   

Portfolio Center

All portfolio management and optimization tools to improve performance of your portfolios
All  Next Launch Portfolio Center
Currently Active Assets on Macroaxis
C   
Purchased over 40 shares of
few hours ago
Traded for 74.96
CRM   
Purchased a lot of shares of
few hours ago
Traded for 152.9
GM   
Purchased over 70 shares of
few hours ago
Traded for 36.03
MSFT   
Purchased over 20 shares of
few hours ago
Traded for 113.54
TWTR   
Purchased over 100 shares of
few hours ago
Traded for 29.52
Additionally take a look at Your Equity Center. Please also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Search macroaxis.com